Clinical Trials Logo

Filter by:
NCT ID: NCT06427044 Not yet recruiting - Clinical trials for Breast Cancer Patients With Chronic Pain After Surgery

Effect of Bupivacaine Liposome Anterior Serratus Deep Block on Chronic Pain After Breast Cancer Surgery: a Randomized Controlled Study

Start date: May 25, 2024
Phase: N/A
Study type: Interventional

This study aims to investigate the effect and influence of liposome bupivacaine anterior serrat plane block on postoperative chronic pain in breast cancer patients, evaluate the therapeutic effect of liposome bupivacaine in postoperative chronic pain, and provide a new method for patients with postoperative chronic pain.

NCT ID: NCT06426758 Not yet recruiting - Graves Disease Clinical Trials

Graves' Disease Induced by Epstein-Barr Virus Lytic Reactivation

Start date: May 30, 2024
Phase:
Study type: Observational

Previous studies have proved that the lytic reactivation of latent Epstein-Barr virus (EBV) was significantly associated with the onset of Graves'disease (GD), however, the morbidity of GD and recurrence rate of hyperthyroidism after antithyroid drugs treatment due to lytic reactivation of EBV is not understood. We will recruit patients with newly diagnosed GD and recurrence of hyperthyroidism after antithyroid drugs treatment. In order to confirm lytic reactivation of EBV, the number of EBV DNA copies,mRNA and protein expression of immediate-early, early and late lytic EBV genes,EBV +TRAb+cells will be tested. The proportion of lytic reactivation of EBV in newly diagnosed GD and recurrence of hyperthyroidism was evaluated.

NCT ID: NCT06426043 Not yet recruiting - Aplastic Anemia Clinical Trials

A Prospective Study on the Treatment of Recurrent/Refractory/Intolerable NSAA With Lusutrombopag

Start date: June 2024
Phase: Phase 4
Study type: Interventional

In a prospective, single-arm study, the efficacy and safety of Lusutrombopag in the treatment of relapsed/refractory/intolerable non-severe aplastic anemia (NSAA) were explored.

NCT ID: NCT06425341 Not yet recruiting - Chronic Hepatitis B Clinical Trials

A Multicenter, Randomized, Open, Parallel-designed Study to Evaluate the Efficacy and Safety of HRS-5635 Injection Alone or in Combination With Other Agents in Patients Treated for Chronic Hepatitis B

Start date: July 1, 2024
Phase: Phase 2
Study type: Interventional

A multicenter, randomized, open, parallel-designed Phase II study to evaluate the efficacy and safety of HRS-5635 injection alone or in combination with other agents in patients treated for chronic hepatitis B.

NCT ID: NCT06425120 Not yet recruiting - Clinical trials for Coronary Heart Disease

Effect of Xuesaitong Soft Capsules on Major Risk Factors in Patients With Coronary Heart Disease

Start date: May 31, 2024
Phase: Phase 4
Study type: Interventional

This trials aims to assess, in 240 eligible patients with coronary heart disease, the effects on level of high-sensitivity C-reactive protein (hsCRP) changes from baseline to 12 weeks of Xuesaitong Soft Capsules.

NCT ID: NCT06424665 Not yet recruiting - Clinical trials for Advanced Solid Tumor, SCLC(Small Cell Lung Cancer) or LCNEC (Large Cell Neuroendocrine Carcinoma)

A Study of FZ-AD005 in Patients With Advanced Solid Tumors

Start date: May 30, 2024
Phase: Phase 1
Study type: Interventional

A First-in-Human, Open Label, Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of FZ-AD005 in Patients with Advanced Solid Tumors.

NCT ID: NCT06424639 Not yet recruiting - Aplastic Anemia Clinical Trials

Luspatercept Plus CsA vs CsA for the Treatment of Newly Diagnosed Non-Transfusion-Dependent NSAA

Start date: May 2024
Phase: Phase 4
Study type: Interventional

In a randomized, controlled clinical trial, the efficacy and safety of rodsipil combined with cyclosporine versus cyclosporine alone in the treatment of newly diagnosed non-transfusion-dependent NSAA were compared.

NCT ID: NCT06424626 Not yet recruiting - Melanoma Clinical Trials

A Trial of AK104 or AK112 in Combination With Axitinib in Patients With Metastatic Mucosal Melanoma

Start date: May 21, 2024
Phase: Phase 1
Study type: Interventional

This study was a phase IB, single-center, open-label, two part(part A involved dose reduction, and part B involved cohort expansion) clinical trial evaluating the safety and clinical activity of AK104 or AK112 in combination with axitinib in patients with advanced mucosal melanoma.

NCT ID: NCT06424314 Not yet recruiting - Weaning Failure Clinical Trials

Exploration of Mechanisms for Weaning Failure

Start date: June 15, 2024
Phase:
Study type: Observational

This study is a prospective physiologic study. The primary study population will be adult invasive tracheal intubated patients with COPD, and investigators will collect relevant demographic data, vital signs, and baseline physiologic parameters of the patients prior to the spontaneous breathing test(SBT). The participants will be divided into a successful withdrawal group and a failed withdrawal group according to the SBT outcome, and the changes in the above parameters during SBT will be compared between the two groups .

NCT ID: NCT06423937 Not yet recruiting - Colorectal Cancer Clinical Trials

Fruquintinib Plus Camrelizumab and HAIC in the Treatment of Non-MSI-H Advanced Colorectal Cancer

Start date: May 2024
Phase: Phase 2
Study type: Interventional

Liver metastasis is the main cause of death in patients with colorectal cancer. The treatment of liver metastasis of colorectal cancer is the key to prolong the survival of patients. The purpose of this study was to investigate the efficacy and safety of fruquintinib combined with Camrelizumab and HAIC regimen in the treatment of non-MSI-H advanced colorectal cancer patients with liver metastasis after first-line standard treatment failure. Compared with the current standard second-line treatment plan, it provides new decisions for clinical practice, in order to reduce the adverse reactions of treatment and improve the tolerance and efficacy of patients. To provide more and more optimized medication options for patients with non-MSI-H advanced colorectal cancer complicated with liver metastasis.